Collegium Pharmaceutical Inc.

Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in extended-release and immediate-release formulations, along with Symproic for opioid-induced constipation. The company employs proprietary DETERx platform technology designed to maintain safety profiles while deterring abuse through various manipulation methods. Headquartered in Stoughton, Massachusetts, and founded in 2002, Collegium serves healthcare providers and patients across the United States, positioning itself as a leader in responsible pain management and ADHD treatment.

¿Quieres entender cómo evaluamos la seguridad de los dividendos? Lee nuestra metodología completa